Danaher Co. (NYSE:DHR) Stake Reduced by Milestones Administradora de Recursos Ltda.

Milestones Administradora de Recursos Ltda. decreased its holdings in shares of Danaher Co. (NYSE:DHR) by 50.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,500 shares of the conglomerate’s stock after selling 1,500 shares during the period. Danaher makes up 0.2% of Milestones Administradora de Recursos Ltda.’s portfolio, making the stock its 27th biggest holding. Milestones Administradora de Recursos Ltda.’s holdings in Danaher were worth $417,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter worth $25,000. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter worth about $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher during the first quarter valued at about $30,000. MFA Wealth Advisors LLC purchased a new stake in Danaher during the second quarter valued at about $51,000. Finally, Financial Connections Group Inc. acquired a new position in shares of Danaher in the second quarter worth about $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,052 shares of company stock valued at $5,878,937 over the last 90 days. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 0.0 %

Shares of Danaher stock traded down $0.10 during midday trading on Wednesday, reaching $242.59. 585,146 shares of the company’s stock traded hands, compared to its average volume of 2,733,231. The company has a market cap of $179.68 billion, a price-to-earnings ratio of 41.15, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a 52 week low of $188.75 and a 52 week high of $281.70. The company’s 50 day simple moving average is $268.40 and its 200 day simple moving average is $260.55. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. Equities analysts expect that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. KeyCorp upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Finally, TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $287.28.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.